As a biotech that's planning to go big on artificial intelligence (AI) for drug development, Recursion Pharmaceuticals (NASDAQ: RXRX) is a decidedly forward-thinking organization. Rather than simply ...

This thesis makes the case for an investment in Recursion Pharmaceuticals operating as a TechBio which "industrializes" the process of drug discovery in contrast to a typical biotech. The difference ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

One way to think about artificial intelligence, in its modern deep learning form, is as a jigsaw puzzle. You have a picture on the box, and you begin to organize your pieces. "I usually start by ...

Recursion Pharmaceuticals' stock has plummeted 57% since February, with significant failures in its lead drug REC-994 and other clinical candidates, raising concerns about its AI-driven drug discovery ...

Recursion hopes to transform the healthcare industry with its innovative drug discovery platform. The small company has gained the interest of Nvidia, which has invested in the business. Together, the ...